

MAN 1 9 2004 ET TRADEMARK

Docket No. CEN 298USANP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on

MAY 13, 2004 (Date of Deposit)

KIRK BAUMEISTER

icant assignee, or Registered Representative

(Signature)

MAY 13, 2004

(Date of Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Lamine Mbow

Patrick Branigan Jill Giles-Komar Linda Snyder George Heavner

Serial No.: 10/600,348

Art Unit: 1645

Filed

: JUNE 20, 2003

Examiner:

For

: METHOD FOR GENERATING MONOCLONAL ANTIBODIES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This copy is supplemental to the last Information Disclosure Statement mailed October 10, 2003.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information

 \boxtimes

accompanied by one of:

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/CEN298USANP/KB the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is

<pre>Statement in Accordance with §1.97(e)</pre>	
(attached); or	
☐ Please charge Deposit Account No. 10-	
0750/CEN298USANP/KB the fee of $$180.00$ as se	t
forth in §1.17(p).	
In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of	of
either a Final Action under §1.113 or a Notice of Allowance	
under §1.311 but before the payment of the Issue Fee.	
Applicant(s) hereby petition(s) for consideration of this	
Information Disclosure Statement. Included are: Statement	in
Accordance with §1.97(e) as set forth below and the fee of	
\$180.00 as set forth in §1.17(p).	
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.	
Copies of references listed on the attached Form 1 1449 are enclosed herewith EXCEPT THAT:	PTO
In view of the voluminous nature of reference [list as appropriate], and the likelihood the these references are available to the Examine copies are not enclosed herewith.	at
If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.	
☐ There are no listed references which are not in the	ne

English language.

The relevance of those listed references which are				
not in the English language is as follows:				
Attached are copies of search report(s) from				
corresponding patent application(s), which are listed on the				
attached Submission Under MPEP 609 D.				
Attached are the following non-published pending				
patent applications which may be deemed relevant, which are				
listed on the attached Submission Under MPEP 609 D.				

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN298USANP/KB. This form is submitted in triplicate.

Respectfully submitted,

KIRK BACMEISTER Reg. No. 33,833

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: MAY 13, 2004



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

nd to a collection of information unless it displays a valid OMB control number.			
Application Number	10/600,348		
Filing Date	June 20, 2003		
First Named Inventor	M. Lamine Mbow		
Group Art Unit	1645		
Examiner Name			
Attorney Docket Number	CEN298USANP		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		HAYASHI ET AL, "Induction of Th2-directed immune responses by IL-4-transduced dendritic cells in mice," VACCINE, April 2000, pages 3097-3105, VOL. 18, ELSEVIER SCIENCE LTD.	
		KIM ET AL, "Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-Y, IL-12, or IL-18 gene adjuvants," JOURNAL OF MEDICAL PRIMATOLOGY, 1999, pages 214-223, Vol. 28, IRELAND.	
		KIM ET AL, "Chemokine Gene Adjuvants Can Modulate Immune Responses Induced by DNA Vaccines," JOURNAL OF INTERFEREON AND CYTOKINE RESEARCH, 2000, pages 487-498, VOL. 20, Mary Ann Liebert, Inc., USA>	
		,	
	,		
	<u> </u>		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: COMMISSIONER FOR PATENTS, P. O. BOX 1450, ALEXANDRIA, VA. 22313-1450...

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

MAY 1 9 7004 W

SUBMISSION UNDER MPEP 609 D

Application Number	10/600,348
Filing Date	June 20, 2003
First Named Inventor	M. Lamine Mbow
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	CEN298USANP

Page 1 of 1

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear Name of Patentee or T⁵ Examiner Initials Cite Applicant of Cited Document Office³ Number⁴ KindCode5 No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Examiner Cite No.1 Initials* PCT Search Report dated September 16, 2003. Examiner Date Signature Considered